Screener
CareDx CDNA Reportable Segment — Research materials and clinical trials expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CareDx in its filing.
Tagged under the XBRL concept cdna:ResearchMaterialsAndClinicalTrialsExpense.
The source filing: CareDx’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001217234-26-000033
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of patient and digital solutions1 | 11,412 | 7,344 |
| Personnel cost | 42,188 | 30,743 |
| Professional and legal fees | 7,912 | 10,192 |
| Research materials and clinical trials expense | 3,831 | 3,174 |
| Depreciation and amortization expense | 3,119 | 2,950 |
| Stock-based compensation expense | 9,767 | 8,931 |
| Litigation settlement expense | 600 | 5,360 |
| Business development and portfolio optimization expense2 | 3,357 | — |
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is CareDx's reportable segment — research materials and clinical trials expense?
- CareDx (CDNA) reported reportable segment — research materials and clinical trials expense of $3.83M in Q1 2026.
- How has CareDx's reportable segment — research materials and clinical trials expense changed year-over-year?
- CareDx's reportable segment — research materials and clinical trials expense increased by 20.7% year-over-year, from $3.17M to $3.83M.
- What is the long-term trend for CareDx's reportable segment — research materials and clinical trials expense?
- Over 3 years (2022 to 2025), CareDx's reportable segment — research materials and clinical trials expense has grown at a -16.4% compound annual growth rate (CAGR), from $17.45M to $10.2M.
- What does reportable segment — research materials and clinical trials expense mean?
- Refers to the direct costs associated with conducting clinical studies and procuring materials necessary for the development and validation of new diagnostic solutions. This investment reflects the company's commitment to innovation and the long-term pipeline of its precision medicine portfolio.
Ask your AI about CareDx's reportable segment — research materials and clinical trials expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude